CU20210094A7 - Inhibidores del inflamasoma nlrp3 - Google Patents

Inhibidores del inflamasoma nlrp3

Info

Publication number
CU20210094A7
CU20210094A7 CU2021000094A CU20210094A CU20210094A7 CU 20210094 A7 CU20210094 A7 CU 20210094A7 CU 2021000094 A CU2021000094 A CU 2021000094A CU 20210094 A CU20210094 A CU 20210094A CU 20210094 A7 CU20210094 A7 CU 20210094A7
Authority
CU
Cuba
Prior art keywords
sup
nlrp3
inhibitors
formula
inflamasome
Prior art date
Application number
CU2021000094A
Other languages
English (en)
Inventor
Christopher Farady
Solovay Catherine Fooks
Nina Gommermann
Philipp Janser
Angela Mackay
Henri Mattes
Nichola Smith
Nikolaus Johannes Stiefl
Eric Vangrevelinghe
Juraj Velcicky
Matt Anette Von
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20210094A7 publication Critical patent/CU20210094A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

<p>La presente invención se refiere a nuevos compuestos de piridazin-3-il fenol de la Fórmula (I):</p> <p>ESPACIO DE LA FÓRMULA</p> <p>en donde R¹, R², R³, R<sup>4</sup>, R<sup>5</sup> y Z están definidos en la presente, que inhiben la actividad del inflamasoma de la proteína 3 del receptor tipo NOD (NLRP3). Estos compuestos son por lo tanto útiles en el tratamiento de enfermedades y trastornos mediados por NLRP3.</p>
CU2021000094A 2019-05-17 2020-05-15 Inhibidores del inflamasoma nlrp3 CU20210094A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962849245P 2019-05-17 2019-05-17
PCT/IB2020/054613 WO2020234715A1 (en) 2019-05-17 2020-05-15 Nlrp3 inflammasome inhibitors

Publications (1)

Publication Number Publication Date
CU20210094A7 true CU20210094A7 (es) 2022-06-06

Family

ID=70779818

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000094A CU20210094A7 (es) 2019-05-17 2020-05-15 Inhibidores del inflamasoma nlrp3

Country Status (28)

Country Link
US (4) US11254653B2 (es)
EP (1) EP3969441A1 (es)
JP (2) JP7558975B2 (es)
KR (1) KR102914339B1 (es)
CN (2) CN113784957B (es)
AR (1) AR119731A1 (es)
AU (1) AU2020277738B2 (es)
BR (1) BR112021022796A2 (es)
CA (1) CA3138226A1 (es)
CL (1) CL2021003012A1 (es)
CO (1) CO2021015030A2 (es)
CR (1) CR20210552A (es)
CU (1) CU20210094A7 (es)
DO (1) DOP2021000228A (es)
EC (1) ECSP21080740A (es)
IL (1) IL287042B2 (es)
JO (1) JOP20210307A1 (es)
MX (1) MX2021013941A (es)
MY (1) MY206068A (es)
PE (1) PE20220133A1 (es)
PH (1) PH12021552885A1 (es)
PY (1) PY2019955A (es)
SA (1) SA521430853B1 (es)
SG (1) SG11202111029PA (es)
TW (1) TWI874398B (es)
UY (1) UY38687A (es)
WO (1) WO2020234715A1 (es)
ZA (1) ZA202107444B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
EP4232455A2 (en) * 2020-10-20 2023-08-30 Sanofi Novel ligands for asialoglycoprotein receptor
CN116507608A (zh) * 2020-11-20 2023-07-28 戴纳立制药公司 化合物、组合物和方法
WO2022135567A1 (zh) * 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
EP4289823A4 (en) * 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
CN116964052A (zh) * 2021-03-04 2023-10-27 詹森药业有限公司 调节nlrp3的4-氨基-6-氧代-哒嗪衍生物
MX2023010310A (es) 2021-03-04 2023-09-12 Janssen Pharmaceutica Nv Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3.
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CA3218212A1 (en) * 2021-04-28 2022-11-03 Astellas Pharma Inc. Substituted triazine compound
AR125818A1 (es) * 2021-05-12 2023-08-16 Hoffmann La Roche Inhibidores de nlrp3
TW202313577A (zh) * 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
CN115433163A (zh) * 2021-06-05 2022-12-06 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
EP4362946A4 (en) * 2021-06-29 2025-05-21 Zomagen Biosciences Ltd Nlrp3 modulators
LT4363406T (lt) 2021-07-02 2025-12-29 Astrazeneca Ab Nlrp3 inflamasomų inhibitoriai
TW202319055A (zh) 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
CR20240093A (es) 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
KR20230066899A (ko) 2021-11-08 2023-05-16 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
WO2023088856A1 (en) * 2021-11-17 2023-05-25 F. Hoffmann-La Roche Ag Heterocyclic nlrp3 inhibitors
WO2023088987A1 (en) 2021-11-19 2023-05-25 F. Hoffmann-La Roche Ag Pyridazine derivatives as inhibitors of nlrp3
US20250074888A1 (en) * 2021-12-29 2025-03-06 Neumora Therapeutics, Inc. Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods
IL314025A (en) * 2022-01-07 2024-08-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and uses thereof
WO2023178099A1 (en) * 2022-03-15 2023-09-21 Zomagen Biosciences Ltd Nlrp3 modulators
CA3246681A1 (en) * 2022-03-25 2023-09-28 Ventus Therapeutics U.S., Inc. PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES
LU501764B1 (en) 2022-03-31 2023-10-02 Leibniz Inst Fuer Naturstoff Forschung Und Infektionsbiologie E V Hans Knoell Inst Hki Gasdermin e expression in human t cells as a marker for proinflammatory t cell functions
JP2025511199A (ja) * 2022-03-31 2025-04-15 ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド Ｎｌｒｐ３インフラマソーム阻害剤
AR129012A1 (es) * 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
JP2025517702A (ja) * 2022-05-13 2025-06-10 ニューモラ セラピューティクス インコーポレイテッド Ｎｌｒｐ３インフラマソームのモジュレーターならびに関連製品および方法
WO2023220715A1 (en) * 2022-05-13 2023-11-16 Ventus Therapeutics U.S., Inc. Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereof
EP4531858A1 (en) * 2022-06-03 2025-04-09 F. Hoffmann-La Roche AG Novel compounds
US20260015357A1 (en) * 2022-07-01 2026-01-15 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
WO2024012551A1 (zh) * 2022-07-14 2024-01-18 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
EP4558499A1 (en) * 2022-07-21 2025-05-28 F. Hoffmann-La Roche AG Nlrp3 inhibitors
CA3261365A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa NEW COMPOUNDS
UY40374A (es) * 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
JP2025526692A (ja) * 2022-08-10 2025-08-15 武田薬品工業株式会社 複素環式化合物
KR20240022938A (ko) 2022-08-12 2024-02-20 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
CN116789674B (zh) * 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
IL319619A (en) 2022-09-23 2025-05-01 Merck Sharp & Dohme Llc Phthalazine derivatives used as NOD-LIKE PROTEIN 3 receptor inhibitors
JPWO2024090469A1 (es) 2022-10-26 2024-05-02
EP4612150A1 (en) * 2022-10-31 2025-09-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
EP4611743A1 (en) * 2022-11-02 2025-09-10 Merck Sharp & Dohme LLC Triazines useful as inhibitors of nod-like receptor protein 3
AU2023371859A1 (en) * 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
WO2024094150A1 (en) * 2022-11-04 2024-05-10 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
EP4615830A1 (en) * 2022-11-09 2025-09-17 F. Hoffmann-La Roche AG Triazinone derivatives as nlrp3 inhibitors
JP2025537237A (ja) * 2022-11-09 2025-11-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
CA3268380A1 (en) * 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag TRIAZINONE DERIVATIVES USED AS NLRP3 INHIBITORS
PE20251845A1 (es) * 2022-12-07 2025-07-17 Hoffmann La Roche Compuestos novedosos como moduladores de la inhibicion de nlrp3
KR20250137593A (ko) * 2022-12-23 2025-09-18 뉴모라 테라퓨틱스, 인코포레이티드 Nlrp3 인플라마솜의 조정제 및 관련 생성물 및 방법
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
KR20250106322A (ko) * 2022-12-28 2025-07-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도
WO2024141534A1 (en) 2022-12-28 2024-07-04 Astrazeneca Ab Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds
TW202440107A (zh) 2022-12-28 2024-10-16 瑞典商阿斯特捷利康公司 Ｎｌｒｐ３炎症小體抑制劑
JP2026504821A (ja) * 2023-01-03 2026-02-10 コディアック サイエンシーズ インコーポレイテッド Ｎｌｒｐ３阻害剤としての有機化合物
WO2024148148A1 (en) * 2023-01-04 2024-07-11 The Trustees Of Columbia University In The City Of New York Pyridazine based small molecule inhibitor of cognitive impairment
CN120569372A (zh) 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
WO2024158941A2 (en) * 2023-01-27 2024-08-02 Mwyngil Therapeutics, Inc. Inhibitors of nlrp3
JP2026504419A (ja) 2023-01-31 2026-02-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｌｒｐ３阻害剤としての２－（ピリダジン－３－イル）－５－（トリフルオロメチル）フェノール
KR20250151413A (ko) 2023-01-31 2025-10-21 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 이미다조[1,2-d][1,2,4]트라이아진
WO2024160694A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS
KR20250134147A (ko) 2023-01-31 2025-09-09 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 피롤로[1,2-d][1,2,4]트리아진 및 피라졸로[1,5-d] [1,2,4]트리아진
AU2024215094A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors
EP4667468A1 (en) 2023-02-14 2025-12-24 Shenzhen Zhongge Biological Technology Co., Ltd. Compound for inhibiting nlrp3, preparation method, and use
WO2024169858A1 (zh) * 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途
WO2024217462A1 (zh) * 2023-04-18 2024-10-24 南京明德新药研发有限公司 五氟化硫取代的芳环化合物及其应用
WO2024248287A1 (ko) * 2023-06-01 2024-12-05 한양대학교 에리카산학협력단 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물
KR20260027946A (ko) 2023-06-02 2026-03-03 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
WO2025026252A1 (en) * 2023-08-02 2025-02-06 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
WO2025036275A1 (zh) * 2023-08-11 2025-02-20 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
WO2025046419A1 (ko) 2023-08-25 2025-03-06 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
TW202532066A (zh) 2023-12-14 2025-08-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之氮雜吲唑衍生物
US20250195511A1 (en) 2023-12-14 2025-06-19 Merck Sharp & Dohme Llc Indazole derivatives useful as inhibitors of nod-like receptor protein 3
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
KR20250101963A (ko) * 2023-12-27 2025-07-04 주식회사 대웅제약 이나보글리플로진을 유효성분으로 포함하는 원형 탈모 예방 또는 치료용 약학 조성물
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2025229146A1 (en) * 2024-05-02 2025-11-06 Sanofi Crystalline form of a pyridazine nlrp3 inhibitor
WO2025232839A1 (en) * 2024-05-09 2025-11-13 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
WO2025252163A1 (zh) * 2024-06-07 2025-12-11 康百达（四川）生物医药科技有限公司 一种哒嗪并环衍生物及其在医药上的应用
WO2026057634A1 (en) * 2024-09-11 2026-03-19 Sanofi Crystalline form of a pyridazine nlrp3 inhibitor
WO2026057747A1 (en) 2024-09-11 2026-03-19 Ac Immune Sa Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510997A1 (fr) 1981-08-10 1983-02-11 Sanofi Sa Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
FR2663326B2 (fr) 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
FR2676444B1 (fr) 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
WO2008058064A1 (en) 2006-11-07 2008-05-15 Lexicon Pharmaceuticals, Inc. Amine-linked multicyclic compounds as inhibitors of the proline transporter
GB0720444D0 (en) * 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010128152A1 (en) 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
BR112012008924A2 (pt) 2009-10-20 2019-09-24 Novartis Ag derivado de glicosídeo e usos do mesmo
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
US8835472B2 (en) * 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
SG11201503697TA (en) 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CA2902686C (en) 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
KR102350357B1 (ko) 2013-11-05 2022-01-14 노파르티스 아게 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CN105979948A (zh) 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
NZ719169A (en) 2013-12-20 2018-08-31 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
DK3143026T3 (da) 2014-05-13 2024-09-30 Novartis Ag Forbindelser og sammensætninger til induktion af chondrogenese
CN103965169A (zh) 2014-05-30 2014-08-06 彭正中 一种化合物及其制备方法与用途
WO2016022626A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
PE20190710A1 (es) 2014-10-24 2019-05-17 Bristol Myers Squibb Co Compuestos de indol carboxamida utiles como inhibidores de cinasas
PT3236953T (pt) 2014-12-24 2021-01-29 Principia Biopharma Inc Dosagem específica de sítio de um inibidor de btk
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
WO2016123229A1 (en) 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
KR102727059B1 (ko) 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
JP6889494B2 (ja) 2015-10-09 2021-06-18 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
PL3371165T3 (pl) 2015-11-04 2022-05-02 Merck Patent Gmbh Inhibitor btk do zastosowania w terapii rakowej
IL294124B2 (en) * 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
RU2728827C2 (ru) 2016-01-05 2020-07-31 Цзянсу Хэнжуй Медицин Ко., Лтд. Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
CN109071524A (zh) 2016-01-15 2018-12-21 布里格姆及妇女医院股份有限公司 作为eaat2活化剂的哒嗪衍生物
CN115054586B (zh) 2016-06-29 2024-08-02 普林斯匹亚生物制药公司 改性的释放制剂
KR101865120B1 (ko) 2016-06-29 2018-06-08 숭실대학교 산학협력단 테스트 노드 기반의 무선 측위 방법 및 그 장치
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
US11344543B2 (en) 2017-07-14 2022-05-31 Innate Tumor Immunity, Inc. NLRP3 modulators
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
MX2020001776A (es) * 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
KR20200057071A (ko) 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
CN112272666A (zh) 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
EP3784665A4 (en) 2018-04-26 2022-01-26 Aurigene Discovery Technologies Limited PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
WO2022135567A1 (zh) 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES

Also Published As

Publication number Publication date
JOP20210307A1 (ar) 2021-11-16
US12139471B2 (en) 2024-11-12
JP2022532354A (ja) 2022-07-14
AU2020277738A1 (en) 2021-11-18
UY38687A (es) 2023-05-15
US20250270188A1 (en) 2025-08-28
PH12021552885A1 (en) 2022-07-25
IL287042B1 (en) 2024-10-01
ZA202107444B (en) 2024-11-27
SA521430853B1 (ar) 2024-08-05
KR102914339B1 (ko) 2026-01-19
US20200361898A1 (en) 2020-11-19
MY206068A (en) 2024-11-27
ECSP21080740A (es) 2021-12-30
CN119732956A (zh) 2025-04-01
US20200361899A1 (en) 2020-11-19
IL287042A (en) 2021-12-01
CN113784957A (zh) 2021-12-10
JP2025004014A (ja) 2025-01-14
TWI874398B (zh) 2025-03-01
JP7558975B2 (ja) 2024-10-01
CN113784957B (zh) 2025-02-28
WO2020234715A1 (en) 2020-11-26
US20220251067A1 (en) 2022-08-11
TW202110809A (zh) 2021-03-16
PE20220133A1 (es) 2022-01-27
EP3969441A1 (en) 2022-03-23
CO2021015030A2 (es) 2021-11-30
IL287042B2 (en) 2025-02-01
MX2021013941A (es) 2022-03-11
AU2020277738B2 (en) 2023-03-02
AR119731A1 (es) 2022-01-05
CL2021003012A1 (es) 2022-09-09
SG11202111029PA (en) 2021-12-30
KR20220008887A (ko) 2022-01-21
BR112021022796A2 (pt) 2022-04-12
PY2019955A (es) 2021-03-04
CR20210552A (es) 2021-11-26
US11254653B2 (en) 2022-02-22
DOP2021000228A (es) 2021-12-15
US11208399B2 (en) 2021-12-28
CA3138226A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
CU20210094A7 (es) Inhibidores del inflamasoma nlrp3
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
EA202091267A1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
CL2020002198A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
MX387394B (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
CR20200358A (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
ECSP18083519A (es) Inhibidores de bromodominios
DOP2010000064A (es) 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
BR112015022462A2 (pt) inibidores de ido
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
EA201291055A1 (ru) Ингибиторы протеинтирозинкиназной активности и их применение для лечения глазных заболеваний
PE20210044A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
MX2018008157A (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.
JOP20190179A1 (ar) نوكليوتيدات ثنائية حلقية كناهضات لـ sting
CO2021001174A2 (es) Inhibidores de ckd8/19
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
UY38133A (es) Nuevos inhibidores de cdk8/19
PA8642901A1 (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa i
PY2003748A (es) Inhibidores de inflamasoma nlrp3
AR134419A1 (es) Compuestos que inhiben la quinasa tipo polo 4
EA202191738A1 (ru) Соединения имидазопиридазина и имидазопиридина и их применение